Gadofosveset

Gadofosveset trisodium
Systematic (IUPAC) name

Trisodium 2-{[(2R)-2-[bis(2-oxido-2-oxoethyl)amino]-3-[(4,4-diphenylcyclohexyl)oxy-oxidophosphoryl]oxypropyl]-[2-[bis(2-oxido-2-oxoethyl)amino]ethyl]amino}acetate
Clinical data
Trade names	Vasovist, Ablavar
Pregnancy category	US: C (Risk not ruled out)
Legal status	US: ℞-only
Routes of administration	Intravenous
Identifiers
CAS Number	193901-90-5
ATC code	V08CA11
PubChem	CID 158440
DrugBank	DB06705
ChemSpider	139381
KEGG	D08005^Y
Chemical data
Formula	C₃₃H₄₀GdN₃Na₃O₁₅P
Molar mass	975.88 g/mol
SMILES [Gd+3].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)C[C@@H](N(CC([O-])=O)CC([O-])=O)COP([O-])(=O)OC3CCC(c1ccccc1)(c2ccccc2)CC3.O
InChI InChI=1S/C33H44N3O14P.Gd.3Na.H2O/c37-28(38)18-34(15-16-35(19-29(39)40)20-30(41)42)17-26(36(21-31(43)44)22-32(45)46)23-49-51(47,48)50-27-11-13-33(14-12-27,24-7-3-1-4-8-24)25-9-5-2-6-10-25;;;;;/h1-10,26-27H,11-23H2,(H,37,38)(H,39,40)(H,41,42)(H,43,44)(H,45,46)(H,47,48);;;;;1H2/q;+3;3*+1;/p-6/t26-;;;;;/m1...../s1 Key:PIZALBORPSCYJU-QSQMUHTISA-H

Gadofosveset (trade names Vasovist, Ablavar) is a gadolinium-based MRI contrast agent. It is used in form of the trisodium salt.^[1]^[2] It acts as a blood pool agent by binding to human serum albumin.

References

Contrast media (V08)

X-ray and CT

Iodinated,
Water soluble

Nephrotropic, high osmolar	Diatrizoic acid^# Metrizoic acid Iodamide Iotalamic acid Ioxitalamic acid Ioglicic acid Acetrizoic acid Iocarmic acid Methiodal Diodone

Nephrotropic, low osmolar	Metrizamide Iohexol^# Ioxaglic acid Iopamidol Iopromide Iotrolan Ioversol Iopentol Iodixanol Iomeprol Iobitridol Ioxilan

Hepatotropic	Iodoxamic acid Iotroxic acid Ioglycamic acid Adipiodone Iobenzamic acid Iopanoic acid Iocetamic acid Sodium iopodate Tyropanoic acid Calcium iopodate

Iodinated,
Water insoluble

Non-iodinated

Barium sulfate^#

MRI

Paramagnetic	Gadolinium-based: Gadobenic acid Gadobutrol Gadodiamide Gadofosveset Gadolinium Gadopentetic acid Gadoteric acid Gadoteridol Gadoversetamide Gadoxetic acid Other: Ferric ammonium citrate Mangafodipir

Superparamagnetic	Ferumoxsil Ferristene Iron oxide, nanoparticles

Other	Perflubron

Ultrasound

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia - version of the Sunday, June 28, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.